Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Sikalas

Vascular Surgery Stony Brook, NY Medical Doctor

NPI 1720307002 CMS profile 168818

Stony Brook University Hospital, Health Sciences Tower,Level 19, Rm090, Stony Brook, NY 11790

Open in the dashboard

General payments

$26,453

255 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Sikalas of Stony Brook, NY is reported in the CMS Open Payments database as having received $26,453 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,306 23
2024 General $2,513 45
2023 General $8,124 59
2022 General $8,593 51
2021 General $2,408 34
2020 General $868 18
2019 General $1,641 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Sikalas
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Nicholas Sikalas were reported at $2,306. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Nicholas Sikalas Vascular Surgery median Middle half National median
2019 $1,641 $796 $226–$2,363 $163
2020 $868 $348 $118–$1,110 $114
2021 $2,408 $471 $158–$1,421 $132
2022 $8,593 $725 $222–$2,183 $149
2023 $8,124 $836 $257–$2,440 $160
2024 $2,513 $909 $252–$2,619 $164
2025 $2,306 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $12,772 38 payments
  2. Tactile Systems Technology Inc $3,267 89 payments
  3. W. L. Gore & Associates, Inc. $2,476 25 payments
  4. Medtronic, Inc. $2,289 35 payments
  5. Cook Medical LLC $1,475 23 payments
  6. Silk Road Medical, Inc. $958 11 payments
  7. Penumbra, Inc. $551 5 payments
  8. Bolton Medical Inc $525 5 payments
  9. Inari Medical, Inc. $328 3 payments
  10. Medtronic Vascular, Inc. $288 3 payments
  11. Other $1,525 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,072 235 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,120 4 payments
  3. Travel and Lodging $2,810 14 payments
  4. Consulting Fee $450 2 payments
Products named General payments · program years 2019–2025
  1. AngioJet Ultra 5000A $5,919 9 payments
  2. EkoSonic $5,184 4 payments
  3. Flexitouch Plus $2,598 68 payments
  4. ENDURANT IIS $1,438 22 payments
  5. Entre Plus $1,323 44 payments
  6. entre $1,247 23 payments
  7. ENROUTE Transcarotid Stent $958 11 payments
  8. ENROUTE Transcarotid Neuroprotection System $958 11 payments
  9. GORE TAG Thoracic Branch Endoprosthesis $909 7 payments
  10. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $875 12 payments
  11. Other $9,982 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

74

Median for Vascular Surgery: 122

Drug cost

$29,117

Median for Vascular Surgery: $14,135

Branded share of claims

66.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 15 $14,666
Eliquis Apixaban Brand 17 $13,682
Triamcinolone Acetonide Generic 12 $340
Cilostazol Generic 13 $267
Clopidogrel Clopidogrel Bisulfate Brand 17 $162

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$212,414

Medicare's payments for the services billed

Medicare patients

473

Average age 75

Services billed

1,316

219 women, 254 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Ischemic heart disease 60%
Diabetes 50%
Chronic kidney disease 38%
Heart failure 35%
Atrial fibrillation 32%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record